Navigating New Oral Treatment Algorithms in CLL

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Program Introduction

EMA Indications: BCR and Bcl-2 Inhibitors for Patients With CLL

Ibrutinib Efficacy in the Frontline Setting

Ibrutinib Efficacy in the Relapsed Setting

Safety of Ibrutinib: Long-Term Follow-Up

Ibrutinib Discontinuation: Clinical Considerations

Idelalisib Plus Rituximab in Relapsed CLL

Idelalisib Plus Ofatumumab in Relapsed CLL

Mechanism of Action: Ibrutinib, Idelalisib, and Venetoclax in CLL

Venetoclax Efficacy in the Relapsed Setting

Safety of Venetoclax: Minimizing Risk for TLS

Availability of Novel Oral Agents

Sequencing Options in Treating Relapsed CLL

Cytogenetic Testing for CLL

Complex Karyotype as Predictor of Outcomes

Treatment Options After Relapsing on Ibrutinib: Del(17p)

Treatment Options After Relapsing on Ibrutinib: No Adverse Deletions or Mutations

Revisiting Use of Chemoimmunotherapy in the Frontline Setting

Treating Relapsed CLL: Looking Ahead

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)